Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. (TNDM) focuses on diabetes management solutions, particularly insulin pumps and related technologies. TNDM stock observed a significant bearish movement in the market today.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.1% on Jan 13, 2026 14:56

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) reported a Q3 loss but exceeded revenue estimates. The company's performance indicates it is navigating market conditions better than anticipated by analysts, despite facing profitability challenges. Investors will be watching for future guidance and how the company plans to achieve sustainable growth and profitability.

https://www.msn.com/en-us/money/topstocks/tandem-diabetes-care-inc-tndm-reports-q3-loss-tops-revenue-estimates/ar-AA1PXdyU?ocid=BingNewsVerp

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss these results. Interested parties can access the webcast via Tandem Diabetes Care’s Investor Center website or register for dial-in details.

https://uk.finance.yahoo.com/news/tandem-diabetes-care-announce-fourth-210500353.html

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Tandem Diabetes Care, Inc. announced its plan to release fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after market close. The company will host a conference call and live webcast on the same day at 4:30 pm Eastern Time to discuss these results. Details for accessing the webcast and dial-in information are provided for interested stakeholders.

https://www.businesswire.com/news/home/20260108448160/en/Tandem-Diabetes-Care-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-19-2026

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Tandem Diabetes Care, Inc. will release its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the market closes. The company will also host a conference call and live webcast on the same day at 4:30 PM Eastern Time to discuss these results. An archive of the webcast will be available for 30 days on Tandem's Investor Center website.

https://finance.yahoo.com/news/tandem-diabetes-care-announce-fourth-210500353.html

Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

This article discusses the anticipation surrounding Tandem Diabetes Care's (TNDM) upcoming Q4 2024 earnings report. Analysts expect a year-over-year revenue decline and a wider loss, with key focus areas including gross margin, pump shipments, and international sales. Investors will be looking for insights into the company's market positioning and future growth strategies.

https://www.msn.com/en-us/money/topstocks/tandem-diabetes-care-tndm-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures/ar-AA1zLfZx?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

Trending Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Down 5.1% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.5% Today

Block Inc. ($XYZ) Stock Forecast: Down 5.0% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.1% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Down 1.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Up 5.1% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.5% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.7% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Up 5.0% Today

Tandem Diabetes Care, Inc. Price History

22.11.2025 - TNDM Stock was up 5.1%

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

31.09.2025 - TNDM Stock was down 6.9%

• The bearish movement in TNDM's stock today may be linked to the announcement of a securities class action investigation by a law firm. Concerns among investors about potential legal implications possibly triggered a sell-off.
• Despite anticipated outperformance in earnings estimates for the upcoming period, uncertainties related to the investigation might have outweighed any positive outlook, resulting in a negative investor sentiment.
• The current mix of positive earnings expectations and legal concerns has generated a varied sentiment, contributing to a bearish trend for TNDM's stock today.

09.00.2026 - TNDM Stock was down 9.7%

• Today's downward movement in TNDM stock could be tied to market expectations for the upcoming Q4 2025 earnings. Analysts foresee a decline in revenue and a wider loss compared to the previous year. Key metrics such as gross margin, pump shipments, and international sales are closely watched, prompting investors to review their positions. Concerns about the company's market position and growth strategies might have shifted market sentiment, leading to a stock sell-off.

10.09.2025 - TNDM Stock was down 5.2%

• A securities class action investigation could have raised concerns among investors, leading to a sell-off of TNDM shares.
• Investor uncertainty regarding the potential outcomes of the investigation might have contributed to the bearish movement in TNDM stock.
• The negative sentiment surrounding the company due to the ongoing legal scrutiny could have overshadowed any positive developments, impacting the stock price negatively.

04.10.2025 - TNDM Stock was up 5.2%

• The bullish movement in TNDM stock today could be attributed to the anticipation of beating earnings estimates in the upcoming report.
• The news of a securities class action investigation might have initially caused some uncertainty in the market, but investors seem to have focused more on the positive expectations for the earnings report.
• Investors may be optimistic about Tandem Diabetes Care's potential for strong financial performance, leading to increased buying interest and driving the stock price higher.
• Overall, the market movement reflects a mix of short-term concerns regarding the investigation and long-term confidence in the company's earnings potential, resulting in a bullish sentiment for TNDM stock.

13.00.2026 - TNDM Stock was down 5.1%

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

16.11.2025 - TNDM Stock was up 6.4%

• The company was upgraded to "Outperform" from "Neutral" by Baird, accompanied by an increased price target. This adjustment signals a favorable outlook on the company's financial future, potentially contributing to the upward movement.
• A previous investigation into a securities class action following a stock decline due to a voluntary medical device correction may have led to initial uncertainty and a decrease in the stock price. However, the subsequent positive outlook and upgrade likely played a role in driving the upward movement.
• While concerns existed regarding pump demand and negative EBITDA, the recent price surge and a possible undervaluation, as indicated by Simply Wall St's DCF model, could have attracted investors, thereby leading to the uptrend.
• In summary, a combination of optimistic analyst assessments, potential undervaluation, and anticipated future growth opportunities probably fueled today's upward movement in Tandem Diabetes Care's stock.

17.08.2025 - TNDM Stock was down 2.7%

• An investigation into potential securities claims on behalf of Tandem Diabetes Care shareholders may have raised concerns and uncertainty among investors, contributing to a bearish movement in the stock.
• An endorsement of Tandem Diabetes Care as a speculative stock for younger investors could have added volatility to the stock, attracting both buyers and sellers and contributing to the bearish trend.
• A contrasting recommendation to buy other stocks like Cintas (NASDAQ: CTAS) and Intuitive Surgical (NASDAQ: ISRG) might have diverted attention and capital away from Tandem Diabetes Care, impacting its stock performance negatively.

20.10.2025 - TNDM Stock was up 5.0%

• Investor optimism regarding TNDM stock is likely due to the recent news of an investigation by the Rosen Law Firm into potential securities claims on behalf of shareholders.
• This development may have boosted investor confidence in the company's outlook.
• The market's reaction suggests that investors are hopeful that any concerns raised in the investigation will be resolved favorably, leading to an increase in the stock price.

05.00.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care (TNDM) saw a significant increase in its stock value due to various positive factors today:
• The company is part of a group of biotech companies leading advancements in diabetes treatments, moving beyond traditional insulin shots towards functional cures and regenerative medicine, which has captured investor interest and confidence in TNDM's future.
• The anticipated growth of the disposable insulin pumps market, where Tandem Diabetes Care plays a pivotal role, suggests a promising future for the company, with the rising adoption of tubeless patch pumps fueling market expansion.
• Recent updates made by Tandem Diabetes Care to its bylaws to strengthen governance rules illustrate a dedication to transparency and accountability, reassuring investors and potentially attracting new interest in the company.
• Significant purchases of Tandem Diabetes Care stock by key executives indicate a belief in the company's direction and future expansion, offering a positive perspective for investors and contributing to the upward movement in the stock price.

01.09.2025 - TNDM Stock was up 7.7%

• Initial uncertainty and bearish sentiment among investors may have been influenced by an ongoing securities fraud investigation.
• If the investigation results do not substantially impact the company, investors may become more confident in Tandem's future prospects, potentially contributing to the bullish movement.
• Market participants seem to view the news positively, indicating that Tandem's financial health and operations may not be significantly impacted by the investigation, resulting in the stock price rise.

10.11.2025 - TNDM Stock was up 6.1%

• The stock of Tandem Diabetes Care (TNDM) experienced a bullish movement following an analyst's target price increase to $23, leading to a 4.5% jump in the stock price.
• Despite the recent gains and analyst optimism, the stock is still down 43.3% year-to-date and trading below its 52-week high, indicating potential room for growth.
• The company's stock rebounded after a previous drop due to a voluntary medical device correction for select t:slim X2 insulin pumps, showcasing resilience in the face of challenges.
• Analysts are re-evaluating Tandem Diabetes Care's valuation, with some intrinsic value estimates below current levels, but competitive pressures and execution challenges pose risks to future growth and margin assumptions.